A mechanistic look at the effects of adversity early in life on cardiovascular disease risk during adulthood

por Loria, A. S., Ho, D. H., Pollock, J. S.
Publicado em 2013

Comparative in vitro activities of newer quinolones against Pseudomonas species and Xanthomonas maltophilia isolated from patients with cancer.

por Rolston, K V, Messer, M, Ho, D H
Publicado em 1990

Comparison of vancomycin disposition in rats with normal and abnormal renal functions.

por Engineer, M S, Ho, D H, Bodey, G P
Publicado em 1981

In vitro studies of BMY-28142, a new broad-spectrum cephalosporin.

por Bodey, G P, Ho, D H, LeBlanc, B
Publicado em 1985

Clinical pharmacology of moxalactam in patients with malignant disease.

por Estey, E H, Weaver, S S, Ho, D H, Bodey, G P
Publicado em 1981

In vitro evaluation of S-25930 and S-25932, two new quinolones, against aerobic gram-negative isolates from cancer patients.

por Rolston, K V, Ho, D H, LeBlanc, B, Bodey, G P
Publicado em 1987

In vitro activity of paldimycin (U-70138F) against gram-positive bacteria isolated from patients with cancer.

por Rolston, K V, LeBlanc, B, Ho, D H, Bodey, G P
Publicado em 1987

In vitro activities of antimicrobial agents against clinical isolates of Flavimonas oryzihabitans obtained from patients with cancer.

por Rolston, K V, Ho, D H, LeBlanc, B, Bodey, G P
Publicado em 1993

In vitro activity of WIN 49375 compared with those of other antibiotics in isolates from cancer patients.

por Garcia, I, Bodey, G P, Fainstein, V, Ho, D H, LeBlanc, B
Publicado em 1984

In vitro susceptibility of Citrobacter species to various antimicrobial agents.

por Samonis, G, Ho, D H, Gooch, G F, Rolston, K V, Bodey, G P
Publicado em 1987

In vitro activity of Ro 23-9424, a dual-action antibacterial agent, against bacterial isolates from cancer patients compared with those of other agents.

por Rolston, K V, Nguyen, H T, Ho, D H, LeBlanc, B, Bodey, G P
Publicado em 1992

Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.

por Dholakia, N, Rolston, K V, Ho, D H, LeBlanc, B, Bodey, G P
Publicado em 1994

Pharmacokinetics of cefoperazone in patients with neoplastic disease.

por Maksymiuk, A W, LeBlanc, B M, Brown, N S, Ho, D H, Bodey, G P
Publicado em 1981

In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients.

por Rolston, K V, Nguyen, H, Messer, M, LeBlanc, B, Ho, D H, Bodey, G P
Publicado em 1990

Clinical pharmacokinetics of aztreonam in cancer patients.

por Jones, P G, Bodey, G P, Swabb, E A, Ho, D H, Fainstein, V, Pasternak, J
Publicado em 1984

In vitro activity of BRL 36650, a new semisynthetic penicillin.

por Hoy, J F, Rolston, K V, Ho, D H, Alvarez, M, Thirolf, P, Bodey, G P
Publicado em 1986

Sensitive radioimmunoassay for vancomycin.

por Fong, K L, Ho, D H, Bogerd, L, Pan, T, Brown, N S, Gentry, L, Bodey, G P
Publicado em 1981

Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method.

por Reuben, A, Anaissie, E, Nelson, P E, Hashem, R, Legrand, C, Ho, D H, Bodey, G P
Publicado em 1989

Effects of hepatic function on vancomycin clinical pharmacology.

por Brown, N, Ho, D H, Fong, K L, Bogerd, L, Maksymiuk, A, Bolivar, R, Fainstein, V, Bodey, G P
Publicado em 1983